These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22840462)

  • 1. Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer.
    Krüger K; Stefansson IM; Collett K; Arnes JB; Aas T; Akslen LA
    Breast; 2013 Jun; 22(3):282-8. PubMed ID: 22840462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying tumour vascularity in non-luminal breast cancers.
    Kraby MR; Opdahl S; Akslen LA; Bofin AM
    J Clin Pathol; 2017 Sep; 70(9):766-774. PubMed ID: 28249942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular proliferation is a prognostic factor in breast cancer.
    Arnes JB; Stefansson IM; Straume O; Baak JP; Lønning PE; Foulkes WD; Akslen LA
    Breast Cancer Res Treat; 2012 Jun; 133(2):501-10. PubMed ID: 21947750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
    J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular proliferation is increased in basal-like breast cancer.
    Nalwoga H; Arnes JB; Stefansson IM; Wabinga H; Foulkes WD; Akslen LA
    Breast Cancer Res Treat; 2011 Dec; 130(3):1063-71. PubMed ID: 21874512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma.
    Vartanian RK; Weidner N
    Am J Pathol; 1994 Jun; 144(6):1188-94. PubMed ID: 7515558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.
    McCarthy NJ; Yang X; Linnoila IR; Merino MJ; Hewitt SM; Parr AL; Paik S; Steinberg SM; Hartmann DP; Mourali N; Levine PH; Swain SM
    Clin Cancer Res; 2002 Dec; 8(12):3857-62. PubMed ID: 12473600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
    Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
    J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
    Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
    Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival.
    Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA
    J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Vascular Proliferation in Molecular Subtypes of Breast Cancer.
    Bujor IS; Cioca A; Ceaușu RA; Veaceslav F; Nica C; Cîmpean AM; Raica M
    In Vivo; 2018; 32(1):79-83. PubMed ID: 29275302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
    Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Allevi G; Bolsi G; Aguggini S; Brunelli A; Betri E; Generali D; Scaratti L; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2002 Jun; 8(6):1816-21. PubMed ID: 12060622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer.
    Papantoniou VJ; Souvatzoglou MA; Valotassiou VJ; Louvrou AN; Ambela C; Koutsikos J; Lazaris D; Christodoulidou JK; Sotiropoulou MG; Melissinou MJ; Perperoglou A; Tsiouris S; Zerva CJ
    Breast Cancer Res; 2004; 6(2):R56-62. PubMed ID: 14979918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor?
    Jacobs TW; Siziopikou KP; Prioleau JE; Raza S; Baum JK; Hayes DF; Schnitt SJ
    Mod Pathol; 1998 Mar; 11(3):259-64. PubMed ID: 9521472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological characteristics of breast cancer at the primary tumour and the involved lymph nodes.
    Dikicioglu E; Barutca S; Meydan N; Meteoglu I
    Int J Clin Pract; 2005 Sep; 59(9):1039-44. PubMed ID: 16115179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
    Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
    Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.